Clinical trials at UC San Diego Health and elsewhere will assess whether tocilizumab can reduce out-of-control inflammation that damages lungs and increases risks for ventilation and death
Researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
Researchers at UC San Diego School of Medicine and three German universities describe an underlying biological basis for myalgic encephalomyelitis/chronic fatigue syndrome, illustrating how efforts by the body to boost immune system protections can come at physiological cost elsewhere.
IN THE NEWS: When New York City's hospitals were overwhelmed with COVID-19 patients this spring, UCI Health trauma surgeon Dr. Sebastian Schubl answered his mentor's call for help. Schubl treated many patients during his week of 12-hour shifts in the intensive care unit at New York-Presbyterian Hospital. It was a…
UCI Health is the first health system in Orange County to offer a left ventricular assist device (LVAD) for patients diagnosed with end-stage heart failure. LVAD is a life-saving treatment for patients with end-stage heart failure who are awaiting heart transplants or those who are not candidates for heart transplant…
To provide helpful advice and informative stories about life during the COVID-19 pandemic, the University of California, Irvine has launched a comprehensive news site – oc-covid19.org – to serve Orange County and regional communities. The site’s editorial content is designed to engage viewers with useful and novel information derived from…
Antibiotic treatment — which depletes gut microbes — drastically changes the parts of a rat’s brain that are activated during opioid addiction and withdrawal.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia.
